SEC Filing | Pediatrix Medical Group, Inc.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

View:

Download DOC

Download PDF

Download XLS

Download XBRL

Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2011

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-12111

MEDNAX, INC.

(Exact name of registrant as specified in its charter)


Florida		26-3667538
(State or other jurisdiction of Incorporation or organization)		(I.R.S. Employer Identification No.)

1301 Concord Terrace Sunrise, Florida		33323
(Address of principal executive offices)		(Zip Code)

(954) 384-0175

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

On October 26, 2011, the registrant had outstanding 48,911,516 shares of Common Stock, par value $.01 per share.

MEDNAX, INC.

INDEX


		Page
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements		3

	Condensed Consolidated Balance Sheets as of September 30, 2011 and December 31, 2010 (Unaudited)		3

	Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2011 and 2010 (Unaudited)		4

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2011 and 2010 (Unaudited)		5

	Notes to Condensed Consolidated Financial Statements (Unaudited)		6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		18

Item 4.	Controls and Procedures		18

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings		19

tem 1A.	Risk Factors		19

Item 6.	Exhibits		19

SIGNATURES			20

EXHIBIT INDEX			21

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

MEDNAX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	September 30, 2011		December 31, 2010
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	35,749	$	26,251
Short-term investments		7,209		17,381
Accounts receivable, net		207,060		181,395
Prepaid expenses		8,882		5,162
Deferred income taxes		68,556		60,579
Other assets		6,547		5,241

Total current assets		334,003		296,009
Investments		35,019		27,393
Property and equipment, net		61,639		42,774
Goodwill		1,683,336		1,601,319
Other assets, net		65,819		70,151

Total assets	$	2,179,816	$	2,037,646

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	200,069	$	207,937
Current portion of long-term capital lease obligations		160		125
Income taxes payable		14,840		12,999

Total current liabilities		215,069		221,061
Line of credit		50,000		146,500
Long-term capital lease obligations		359		56
Long-term professional liabilities		111,693		99,786
Deferred income taxes		88,829		74,066
Other liabilities		51,646		48,723

Total liabilities		517,596		590,192

Commitments and contingencies

Shareholders’ equity:
Preferred stock; $.01 par value; 1,000 shares authorized; none issued		—		—
Common stock; $.01 par value; 100,000 shares authorized; 48,879 and 47,937 shares issued and outstanding, respectively		489		479
Additional paid-in capital		714,209		659,091
Retained earnings		947,522		787,884

Total shareholders’ equity		1,662,220		1,447,454

Total liabilities and shareholders’ equity	$	2,179,816	$	2,037,646

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

MEDNAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2010			2011			2010
Net patient service revenue	$	407,665		$	351,058		$	1,183,350		$	1,033,079

Operating expenses:
Practice salaries and benefits		246,687			211,884			725,873			634,048
Practice supplies and other operating expenses		16,718			13,980			48,061			41,137
General and administrative expenses		43,010			37,499			127,510			114,762
Depreciation and amortization		6,213			6,321			18,026			16,107

Total operating expenses		312,628			269,684			919,470			806,054

Income from operations		95,037			81,374			263,880			227,025
Investment income		337			438			991			1,107
Interest expense		(1,056	)		(481	)		(2,955	)		(2,309	)

Income before income taxes		94,318			81,331			261,916			225,823
Income tax provision		36,077			20,061			102,278			76,932

Net income	$	58,241		$	61,270		$	159,638		$	148,891

Per common and common equivalent share data:

Net income:
Basic	$	1.21		$	1.31		$	3.36		$	3.20

Diluted	$	1.19		$	1.29		$	3.28		$	3.14

Weighted average shares:
Basic		47,990			46,788			47,564			46,535

Diluted		48,935			47,482			48,683			47,426

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

MEDNAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)


	Nine Months Ended September 30,
	2011			2010
Cash flows from operating activities:
Net income	$	159,638		$	148,891
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization		18,026			16,107
Accretion of contingent consideration liabilities		817			717
Stock-based compensation expense		20,037			19,099
Deferred income taxes		5,554			6,232
Changes in assets and liabilities:
Accounts receivable		(25,665	)		(10,278	)
Prepaid expenses and other assets		(5,026	)		3,632
Other assets		4,021			(1,087	)
Accounts payable and accrued expenses		(13,182	)		(51,757	)
Income taxes payable		1,738			17,558
Long-term professional liabilities		11,907			6,347
Other liabilities		3,056			18

Net cash provided from operating activities		180,921			155,479

Cash flows from investing activities:
Acquisition payments, net of cash acquired		(79,928	)		(64,136	)
Purchases of investments		(26,039	)		(21,422	)
Proceeds from maturities of investments		28,585			11,600
Purchases of property and equipment		(28,622	)		(10,054	)

Net cash used in investing activities		(106,004	)		(84,012	)

Cash flows from financing activities:
Payments on line of credit		(484,000	)		(409,500	)
Borrowings on line of credit		387,500			359,500
Payments of contingent consideration liabilities		(3,700	)		(1,600	)
Payments on capital lease obligations		(413	)		(201	)
Excess tax benefit from exercises of stock options and vesting of restricted stock		6,886			2,253
Excess tax benefit related to resolution of income tax matters		—			3,394
Proceeds from issuance of common stock		28,308			9,571

Net cash used in financing activities		(65,419	)		(36,583	)

Net increase in cash and cash equivalents		9,498			34,884
Cash and cash equivalents at beginning of period		26,251			26,503

Cash and cash equivalents at end of period	$	35,749		$	61,387

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

MEDNAX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2011

(Unaudited)

1.	Basis of Presentation and New Accounting Pronouncements:

The accompanying unaudited Condensed Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, “MDX”) together with the accounts of MDX’s affiliated professional associations, corporations and partnerships (the “affiliated professional contractors”). MDX has contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms “MEDNAX” and the “Company” refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.

The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Condensed Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K (the “Form 10-K”).

Reclassifications have been made to certain prior period financial statements to conform with the current quarter presentation. Specifically, the Company reclassified $99.8 million of its $111.7 million of professional liabilities as of December 31, 2010 from accounts payable and accrued expenses to long-term professional liabilities. This represents the long-term portion that was previously reported as a current liability.

New Accounting Pronouncements

In January 2010, the accounting guidance related to fair value measurements was amended. The amendment requires expanded disclosure about assets and liabilities within Level 3. The new guidance became effective for the Company on January 1, 2011.

In December 2010, the accounting guidance related to pro forma revenue and earnings disclosure requirements for business combinations was clarified to address diversity in practice. The Company adopted this guidance prospectively for business combinations occurring on or after January 1, 2011.

In September 2011, the accounting guidance related to goodwill impairment testing was amended to allow a company to first assess qualitative factors to determine whether performing the current two-step process is necessary. Under this option, the calculation of a reporting unit’s fair value is not required unless, as a result of the qualitative assessment, it is more likely than not that the fair value of the reporting unit is less than the unit’s carrying amount. The amendment becomes effective on January 1, 2012, with early adoption permitted. The adoption of this guidance will not have an impact on the Company’s Condensed Consolidated Financial Statements.

2.	Cash Equivalents and Investments:

As of September 30, 2011 and December 31, 2010, the Company’s cash equivalents consisted entirely of money market funds with a fair value of $15.9 million and $11.7 million, respectively.

Investments consist of municipal debt securities, federal home loan securities and certificates of deposit. Investments with remaining maturities of less than one year are classified as short-term investments. Investments classified as long-term have maturities of one year to six years.

The Company intends and has the ability to hold its held-to-maturity securities to maturity, and therefore carries such investments at amortized cost in accordance with the provisions of the accounting guidance for investments in debt and equity securities. Held-to-maturity securities are not subject to the fair value disclosure requirements.

Investments held at September 30, 2011 and December 31, 2010, are summarized as follows (in thousands):


	September 30, 2011				December 31, 2010
	Short-Term		Long-Term		Short-Term		Long-Term
Municipal debt securities	$	7,209	$	20,518	$	16,901	$	11,327
Federal home loan securities		—		14,501		—		16,066
Certificates of deposit		—		—		480		—

	$	7,209	$	35,019	$	17,381	$	27,393

3.	Fair Value Measurements:

In accordance with the accounting guidance for fair value measurements and disclosures, the Company carries its money market funds at fair value. In accordance with the three-tier fair value hierarchy under this guidance, the Company determined the fair value using quoted market prices, a Level 1 input as defined under the accounting guidance for fair value measurements. At September 30, 2011 and December 31, 2010, the Company’s money market funds had a carrying amount of $15.9 million and $11.7 million, respectively.

The Company also carries the cash surrender value of life insurance related to its deferred compensation arrangements at fair value. The investments underlying the life insurance contracts consist primarily of exchange traded equity securities and mutual funds with quoted prices in active markets. In accordance with the three-tier fair value hierarchy, the Company determined the fair value using the cash surrender value of the life insurance, a Level 2 input as defined under the accounting guidance for fair value measurements. At September 30, 2011 and December 31, 2010, the Company’s cash surrender value of life insurance had a carrying amount of $11.6 million and $12.5 million, respectively.

In addition, the Company carries its contingent consideration liabilities related to acquisitions completed after January 1, 2009 at fair value. In accordance with the three-tier fair value hierarchy, the Company determined the fair value of its contingent consideration liabilities using the income approach with assumed discount rates and payment probabilities. The income approach uses Level 3, or unobservable inputs as defined under the accounting guidance for fair value measurements. As of September 30, 2011 and December 31, 2010, the Company’s contingent consideration liabilities related to acquisitions completed after January 1, 2009 had a fair value of $30.7 million and $24.8 million, respectively. See Note 6 for more information regarding the Company’s contingent consideration liabilities recorded during the nine months ended September 30, 2011.

The carrying amounts of cash equivalents, short-term investments, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying values of long-term investments, line of credit and capital lease obligations approximate fair value.

4.	Accounts Receivable:

Accounts receivable, net consists of the following (in thousands):


	September 30, 2011			December 31, 2010
Gross accounts receivable	$	721,147		$	603,372
Allowance for contractual adjustments and uncollectibles		(514,087	)		(421,977	)

	$	207,060		$	181,395

5.	Property and Equipment:

During the nine months ended September 30, 2011, the Company completed the purchase of an office building for approximately $18.5 million.

6.	Business Acquisitions:

During the nine months ended September 30, 2011, the Company completed the acquisition of seven physician group practices for total consideration of $81.0 million, consisting of $72.3 million in cash and $8.7 million of contingent consideration. In connection with these acquisitions, the Company recorded goodwill of $77.2 million, other intangible assets consisting primarily of physician and hospital agreements of $4.8 million, fixed assets of $0.2 million and other liabilities of $1.2 million. The Company has not yet completed the purchase price allocation for a certain physician group practice acquired during the nine months ended September 30, 2011, but management does not believe the additional adjustments will be material. These acquisitions expand the Company’s national network of physician practices. The Company expects to improve the results of these physician practices through improved commercial contracting, improved collections, identification of growth initiatives, as well as operating and cost savings based upon the significant infrastructure it has developed.

The contingent consideration of $8.7 million recorded during the nine months ended September 30, 2011 is related to agreements to pay additional amounts based on the achievement of certain performance measures for up to four years ending after the acquisition dates. The accrued contingent consideration related to these acquisitions was recorded at acquisition-date fair value using the income approach with assumed discount rates ranging from 3.0% to 6.0% over the applicable terms and an assumed payment probability of 100% for each of the applicable years. The range of the undiscounted amount the Company could pay under these contingent consideration agreements is between $0 and $9.6 million.

During the nine months ended September 30, 2011, the Company paid approximately $11.3 million for contingent consideration related to certain prior-period acquisitions, of which $5.0 million was accrued at December 31, 2010. In connection with prior-period acquisitions, the Company also recorded additional intangible assets consisting primarily of physician and hospital agreements of $1.3 million, fixed assets of approximately $1.0 million and other liabilities of $0.8 million during the nine months ended September 30, 2011. The Company expects that approximately $45.5 million of the $82.0 million of goodwill recorded during the nine months ended September 30, 2011 will be deductible for tax purposes.

The results of operations of the seven practices acquired during the nine months ended September 30, 2011 have been included in the Company’s Condensed Consolidated Financial Statements from their respective dates of acquisition. The following unaudited pro forma information combines the consolidated results of operations of the Company on a GAAP basis and the acquisitions completed during 2011 and 2010 as if the transactions had occurred on January 1, 2010 (in thousands, except for per share data):


	Nine Months Ended September 30,
	2011		2010
Net patient service revenue	$	1,206,979	$	1,168,932
Net income	$	163,469	$	177,986
Net income per share:
Basic	$	3.44	$	3.82
Diluted	$	3.36	$	3.75
Weighted average shares:
Basic		47,564		46,535
Diluted		48,683		47,426

The pro forma results do not necessarily represent results which would have occurred if the acquisitions had taken place at the beginning of the periods, nor are they indicative of the results of future combined operations.

7.	Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following (in thousands):


	September 30, 2011		December 31, 2010
Accounts payable	$	9,835	$	9,581
Accrued salaries and bonuses		114,014		132,221
Accrued payroll taxes and benefits		31,018		26,122
Accrued professional liabilities		11,688		11,876
Accrual for uncertain tax positions		10,452		10,948
Other accrued expenses		23,062		17,189

	$	200,069	$	207,937

The net decrease in accrued salaries and bonuses of $18.2 million, from $132.2 million at December 31, 2010 to $114.0 million at September 30, 2011, is primarily due to the payment of performance-based incentive compensation during the first quarter of 2011, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2011. A majority of the Company’s payments for performance-based incentive compensation is paid annually in the first quarter.

8.	Income Taxes:

During the third quarter of 2010, the Company reached a resolution with taxing authorities on certain income tax matters that were under review. In connection with this resolution, the Company recorded a reduction in reserves for uncertain tax positions of $9.6 million, excluding interest of $4.7 million and also recorded a reduction in its income tax provision of $10.9 million. In addition, the resolution resulted in an increase in additional paid-in capital of $3.4 million for excess tax benefits related to stock-based awards, which increased the Company’s cash flow from financing activities.

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the nine months ended September 30, 2010 (in thousands):


	Nine Months Ended September 30, 2010
Balance at December 31, 2009	$	49,416
Increases related to prior year tax positions		374
Decreases related to prior year tax positions		(9,569	)
Increases related to current year tax positions		1,696
Settlements		(605	)

Balance at September 30, 2010	$	41,312

The Company’s effective income tax rate was 38.3% and 39.0% for the three and nine months ended September 30, 2011, respectively, compared to 24.7% and 34.1% for the three and nine months ended September 30, 2010, respectively. The Company’s effective income tax rate was favorably impacted in both 2010 periods by the $10.9 million reduction in its income tax provision resulting from the resolution of the tax matters.

9.	Common and Common Equivalent Shares:

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the applicable period. Potential common shares consist of outstanding options and non-vested restricted and deferred stock calculated using the treasury stock method. Under the treasury stock method, the Company includes the assumed excess tax benefits related to the potential exercise or vesting of its stock-based awards using the difference between the average market price for the applicable period less the option price, if any, and the fair value of the stock-based award on the date of grant multiplied by the applicable tax rate.

The calculation of shares used in the basic and diluted net income per share calculation for the three and nine months ended September 30, 2011 and 2010 is as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2011		2010		2011		2010
Weighted average number of common shares outstanding		47,990		46,788		47,564		46,535
Weighted average number of dilutive common share equivalents		945		694		1,119		891

Weighted average number of common and common equivalent shares outstanding		48,935		47,482		48,683		47,426

Antidilutive securities not included in the dilutive earnings per share calculation		42		1,382		47		737

10.

Stock Incentive Plans and Stock Purchase Plans:

The terms of the Company’s 2008 Incentive Compensation Plan (the “2008 Incentive Plan”) provide for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. As provided in the 2008 Incentive Plan, no additional grants can be made from the Company’s prior incentive plans, except that new awards will be permitted under the 2004 Incentive Compensation Plan (the “2004 Incentive Plan”) to the extent that shares previously granted under the 2004 Incentive Plan are forfeited, expire or terminate. Under the 2008 Incentive Plan, a total of six million shares were available for the granting of awards, inclusive of the number of shares remaining available for grant under the 2004 Incentive Plan as of May 23, 2008. To date, the only equity awards made by the Company under the 2008 Incentive Plan are for stock options, restricted stock and deferred stock. Collectively, the Company’s prior incentive plans and the 2008 Incentive Plan are referred to as the Stock Incentive Plans.

Under the 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards vest on a cliff basis over a term of five years upon the fulfillment of specified service-based and performance-based conditions or upon the satisfaction of specified performance-based conditions through December 31, 2018. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the nine months ended September 30, 2011, the Company granted 426,708 shares of restricted and deferred stock to its employees and 41,400 stock options to its non-employee directors under the Stock Incentive Plans. At September 30, 2011, the Company had approximately 1.3 million shares available for future grants and awards under the Stock Incentive Plans.

Under the Company’s 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the “Non-Qualified Plan”), employees are permitted to purchase the Company’s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. During the nine months ended September 30, 2011, 87,275 shares were issued under the Non-Qualified Plan. At September 30, 2011, the Company had approximately 587,000 shares reserved for issuance under the Non-Qualified Plan.

During the three and nine months ended September 30, 2011 and 2010, the Company recognized approximately $6.8 million and $20.0 million, and $6.7 million and $19.1 million, respectively, of stock-based compensation expense related to the Stock Incentive Plans and the Non-Qualified Plan. The net excess tax benefit recognized in additional paid-in capital related to the vesting of restricted stock and the exercise of stock options for the nine months ended September 30, 2011 was approximately $6.8 million.

11.

Commitments and Contingencies:

In September 2006, the Company entered into a settlement agreement with the Department of Justice and a relator who initiated a “qui tam” complaint against the Company relating to its billing practices for services provided from January 1996 through December 1999 that were reimbursed by Medicaid, the Federal Employees Health Benefit

program, and the United States Department of Defense’s TRICARE program for military dependents and retirees (the “Settlement Agreement”). As part of the Settlement Agreement, the Company was under a five-year Corporate Integrity Agreement (“CIA”) with the Office of Inspector General of the Department of Health and Human Services (the “OIG”) which expired on September 20, 2011. A final report regarding the Company’s compliance with the CIA will be filed with the OIG. Although the term of the CIA has expired, the Company intends to continue the existence of its comprehensive Compliance Plan which provides for policies and procedures aimed at promoting compliance with healthcare laws and regulations.

In July 2007, the Audit Committee of the Company’s Board of Directors concluded a comprehensive review of the Company’s historical practices related to the granting of stock options. In connection with the review, the Company had discussions with the U.S. Attorney’s office for the Southern District of Florida concerning the matters covered by the review and, in response to a subpoena received in December 2007, provided the office with various documents and information related to the Company’s stock option granting practices. The Company intends to fully cooperate with the U.S. Attorney’s office if there is any additional activity with respect to this matter. In March 2009, the Company settled an investigation by the Securities and Exchange Commission relating to this matter by entering into a consent decree.

The Company expects that additional audits, inquiries and investigations from government authorities and agencies will continue to occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows, and the trading price of its common stock.

In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated physicians. The Company’s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company’s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant defense costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition or results of operations. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows, and the trading price of its common stock.

Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company’s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company’s business, financial condition and results of operations.

12.

Subsequent Event:

On October 21, 2011, the Company entered into an amended and restated credit agreement (“Amended and Restated Line of Credit”) which increased the borrowing capacity thereunder to $500 million from $350 million. The Amended and Restated Line of Credit matures on October 21, 2016.

The Amended and Restated Line of Credit, which is guaranteed by substantially all of the Company’s subsidiaries and affiliated professional associations and corporations, includes (1) a $50 million sub-facility for the issuance of letters of credit and (2) a $25 million sub-facility for swingline loans. The Amended and Restated Line of Credit may be increased up to $570 million, subject to the satisfaction of specified conditions. At the Company’s option, borrowings under the Amended and Restated Line of Credit (other than swingline loans) bear interest at (1) the alternate base rate (defined as the highest of (i) the Wells Fargo Bank, National Association prime rate, (ii) the Federal Funds Rate plus 1/2 of 1% and (iii) one month LIBOR plus 1%) or (2) the LIBOR rate, as defined in the Amended and Restated Line of Credit, plus, an applicable margin rate ranging from 0.125% to 0.5% for alternate base rate borrowings and 1.125% to 1.5% for LIBOR rate borrowings, in each case based on the Company’s consolidated leverage ratio. Swingline loans bear interest at the alternate base rate plus the applicable margin rate. The Company is subject to certain covenants and restrictions specified in the Amended and Restated Line of Credit, including covenants that require the Company to maintain a minimum fixed charge coverage ratio and not to exceed a specified consolidated leverage ratio, to comply with laws, and restrict the Company from paying dividends and making certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended and Restated Line of Credit, notwithstanding the Company’s ability to meet its debt service obligations. The Amended and Restated Line of Credit includes various customary remedies for the lenders following an event of default.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K. As used in this Quarterly Report, the terms “MEDNAX”, the “Company”, “we”, “us” and “our” refer to MEDNAX, Inc. and its consolidated subsidiaries (collectively “MDX”), together with MDX’s affiliated professional associations, corporations and partnerships (“affiliated professional contractors”). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico.

Overview

MEDNAX is a leading provider of physician services including newborn, maternal-fetal, pediatric subspecialty, and anesthesia care. Our national network is composed of affiliated physicians, including those who provide neonatal clinical care in 34 states and Puerto Rico, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications. We also have affiliated physicians who provide maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network includes other pediatric subspecialists, including those who provide pediatric cardiology care, pediatric intensive care and hospital-based pediatric care. In addition, we have physicians who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management.

During the nine months ended September 30, 2011, we completed the acquisition of seven physician group practices consisting of three maternal-fetal medicine practices, one neonatology practice, one pediatric cardiology practice, one other pediatric subspecialty practice and one anesthesiology practice. During the nine months ended September 30, 2010, we completed the acquisition of eight physician group practices consisting of six neonatology practices, one maternal-fetal medicine practice and one pediatric cardiology practice. Based on past results, we expect that we can improve the results of these practices through improved commercial contracting, improved collections, identification of growth initiatives, as well as operating and cost savings, based upon the significant infrastructure we have developed.

Our results of operations for the nine months ended September 30, 2011 and 2010 include the results of operations for these physician group practices from their respective dates of acquisition and therefore are not comparable in some respects.

The United States is continuing to be affected by unfavorable economic conditions, and the number of unemployed workers remains significant. During the nine months ended September 30, 2011, the percentage of our patient services being reimbursed under government-sponsored programs remained relatively stable as compared to the same period in 2010. However, in other periods, including the three months ended September 30, 2011, there have been shifts toward government-sponsored programs. We could experience additional shifts if economic conditions do not improve or if they deteriorate further. Payments received from government-sponsored programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, many states continue to experience lower than anticipated revenue and continue to face significant budget shortfalls. These shortfalls could lead to reduced or delayed funding for state Medicaid programs and, in turn, reduced or delayed reimbursement for physician services.

In March 2010, the “Patient Protection and Affordable Care Act,” (the “Healthcare Reform Act”), was enacted. The Healthcare Reform Act contains a number of provisions that could affect us over the next several years. These provisions include establishing health insurance exchanges to facilitate the purchase of qualified health plans, expanding Medicaid eligibility, subsidizing insurance premiums and creating incentives for businesses to provide healthcare benefits. Other provisions contain changes to healthcare fraud and abuse laws and expand the scope of the Federal False Claims Act.

Many of the Healthcare Reform Act’s most significant reforms do not take effect until 2014 and thereafter, and their details will be shaped significantly by implementing regulations that have yet to be proposed. Moreover, enactment of the Healthcare Reform Act has been controversial and has prompted numerous legal challenges to its constitutionality as well as efforts to modify or repeal the law now under consideration in Congress. As a result, we cannot predict with any assurance the ultimate effect of the Healthcare Reform Act on our Company, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations or cash flows.

The following discussion contains forward-looking statements. Please see the Company’s most recent Annual Report on Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see “Caution Concerning Forward-Looking Statements” below.

Results of Operations

Three Months Ended September 30, 2011 as Compared to Three Months Ended September 30, 2010

Our net patient service revenue increased $56.6 million, or 16.1%, to $407.7 million for the three months ended September 30, 2011, as compared to $351.1 million for the same period in 2010. Of this $56.6 million increase, $39.2 million, or 69.3%, was attributable to revenue generated from acquisitions completed after June 30, 2010. Same-unit net patient service revenue increased $17.4 million, or 5.0%, for the three months ended September 30, 2011. The change in same-unit net patient service revenue was the result of an increase in revenue of approximately $10.7 million, or 3.1%, related to net reimbursement-related factors and an increase of $6.7 million, or 1.9%, from higher overall patient service volumes across all of our specialties. The increase in revenue of $10.7 million related to net reimbursement-related factors was primarily due to improved commercial-payor contracting and the flow through of revenue from modest price increases, partially offset by a decrease in revenue caused by an increase in the percentage of our patients being enrolled in government-sponsored programs. The increase in revenue of $6.7 million from higher patient service volumes is related to growth across all of our services. Same units are those units at which we provided services for the entire current period and the entire comparable period.

Practice salaries and benefits increased $34.8 million, or 16.4%, to $246.7 million for the three months ended September 30, 2011, as compared to $211.9 million for the same period in 2010. This $34.8 million increase was primarily attributable to increased costs associated with new physicians and other staff to support acquisition-related growth and growth at existing units, of which $22.9 million was related to salaries and $11.9 million was related to benefits and incentive compensation.

Practice supplies and other operating expenses increased $2.7 million, or 19.6%, to $16.7 million for the three months ended September 30, 2011, as compared to $14.0 million for the same period in 2010. The increase was primarily attributable to practice supply and other costs of $1.6 million related to anesthesiology, hospital-based and hearing screen program acquisitions and practice supply and other costs at our existing units of $1.1 million.

General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician group practices. General and administrative expenses increased $5.5 million, or 14.7%, to $43.0 million for the three months ended September 30, 2011, as compared to $37.5 million for the same period in 2010. This increase of $5.5 million is attributable to the overall growth of the Company, of which $3.5 million related to our existing units and $2.0 was attributable to acquisition-related growth. General and administrative expenses as a percentage of net patient service revenue decreased slightly to 10.6% for the three months ended September 30, 2011, as compared to 10.7% for the three months ended September 30, 2010 and continue to grow at a rate slower than the rate of revenue growth.

Depreciation and amortization expense decreased $0.1 million, or 1.7%, to $6.2 million for the three months ended September 30, 2011, as compared to $6.3 million for the same period in 2010. Depreciation and amortization expense for the three months ended September 30, 2010 included $1.2 million of accelerated amortization expense related to the termination of a hospital contract associated with a prior acquisition. Depreciation and amortization expense for the three months ended September 30, 2011 includes a $1.1 million increase attributable to the amortization of intangible assets related to acquisitions and the depreciation of fixed asset additions.

Income from operations increased $13.6 million, or 16.8%, to $95.0 million for the three months ended September 30, 2011, as compared to $81.4 million for the same period in 2010. Our operating margin increased slightly to 23.3% for the three months ended September 30, 2011, as compared to 23.2% for the same period in 2010.

We recorded net interest expense of $0.7 million for the three months ended September 30, 2011, as compared to $43,000 for the same period in 2010. The increase in net interest expense was primarily due to higher average borrowings under our $350 million revolving credit facility (“Line of Credit”) and a lower rate of return on our investments, partially offset by a lower effective interest rate on our Line of Credit. Interest expense for the three months ended September 30, 2011 and 2010 consisted primarily of interest charges, commitment fees and amortized debt costs associated with our Line of Credit and accretion expense related to our contingent consideration liabilities.

Our effective income tax rate was 38.3% for the three months ended September 30, 2011, as compared to 24.7% for the three months ended September 30, 2010. The income tax rate for the three months ended September 30, 2010 reflects a $10.9 million reduction in our income tax provision resulting from the resolution of certain matters that were under review with taxing authorities. Excluding the favorable impact of the tax matters resolution, our effective income tax rate was 38.1% for the three months ended September 30, 2010. We believe that excluding the favorable impact from the tax matters resolution provides a more meaningful comparison of the effective income tax rate.

Net income decreased 5.1% to $58.2 million for the three months ended September 30, 2011, as compared to $61.3 million for the same period in 2010. Net income for the three months ended September 30, 2010 includes a $10.9 million increase related to a reduction in our income tax provision resulting from the resolution of certain matters that were under review with taxing authorities. Excluding the favorable impact of the tax matters resolution, our net income of $58.2 million increased 15.7% as compared to $50.3 million for the three months ended September 30, 2010. We believe that excluding the favorable impact from the tax matters resolution provides more meaningful comparison of net income.

Diluted net income per common and common equivalent share was $1.19 on weighted average shares outstanding of 48.9 million for the three months ended September 30, 2011, as compared to $1.29 on weighted average shares outstanding of 47.5 million for the same period in 2010. Diluted net income per common and common equivalent share for the three months ended September 30, 2010 reflects a $10.9 million reduction in our income tax provision, or $0.23 per common and common equivalent share, resulting from the resolution of certain matters that were under review with taxing authorities. Excluding the favorable impact of the tax matters resolution, our diluted net income per common and common equivalent share was $1.06 for the three months ended September 30, 2010. We believe that excluding the favorable impact from the tax matters resolution provides a more meaningful comparison of diluted net income per common and common equivalent share.

Nine Months Ended September 30, 2011 as Compared to Nine Months Ended September 30, 2010

Our net patient service revenue increased $150.3 million, or 14.6%, to $1.18 billion for the nine months ended September 30, 2011, as compared to $1.03 billion for the same period in 2010. Of this $150.3 million increase, $112.7 million, or 75.0%, was attributable to revenue generated from acquisitions completed after December 31, 2009. Same-unit net patient service revenue increased $37.6 million, or 3.7%, for the nine months ended September 30, 2011. The change in same-unit net patient service revenue was the result of an increase in revenue of approximately $23.3 million, or 2.3%, related to net reimbursement-related factors and an increase of $14.3 million, or 1.4%, from higher overall patient service volumes across our specialties. The increase in revenue of $23.3 million related to net reimbursement-related factors was primarily due to improved commercial-payor contracting and the flow through of revenue from modest price increases, partially offset by a decrease in revenue caused by an increase in the percentage of our patients being enrolled in government-sponsored programs. The increase in revenue of $14.3 million from higher patient service volumes is related to growth across our services, primarily in our neonatal, anesthesia and pediatric cardiology practices. Same units are those units at which we provided services for the entire current period and the entire comparable period.

Practice salaries and benefits increased $91.9 million, or 14.5%, to $725.9 million for the nine months ended September 30, 2011, as compared to $634.0 million for the same period in 2010. This $91.9 million increase was primarily attributable to increased costs associated with new physicians and other staff to support acquisition-related growth and growth at existing units, of which $64.2 million was related to salaries and $27.7 million was related to benefits and incentive compensation.

Practice supplies and other operating expenses increased $6.9 million, or 16.8%, to $48.1 million for the nine months ended September 30, 2011, as compared to $41.1 million for the same period in 2010. The increase was primarily attributable to practice supply and other costs of $4.4 million related to anesthesiology, hospital-based, hearing screen program and office-based acquisitions. In addition, practice supply and other costs at our existing units increased by $2.5 million.

General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician group practices. General and administrative expenses increased $12.7 million, or 11.1%, to $127.5 million for the nine months ended September 30, 2011, as compared to $114.8 million for the same period in 2010. This increase of $12.7 million is attributable to the overall growth of the Company, of which $7.0 million related to our existing units and $5.7 was attributable to acquisition-related growth. General and administrative expenses as a percentage of net patient service revenue decreased to 10.8% for the nine months ended September 30, 2011, as compared to 11.1% for the nine months ended September 30, 2010 and continue to grow at a rate slower than the rate of revenue growth.

Depreciation and amortization expense increased $1.9 million, or 11.9%, to $18.0 million for the nine months ended September 30, 2011, as compared to $16.1 million for the same period in 2010. Depreciation and amortization expense for the nine months ended September 30, 2011 includes a $3.1 million increase attributable to the amortization of intangible assets related to acquisitions and the depreciation of fixed asset additions. Depreciation and amortization expense for the nine months ended September 30, 2010 included $1.2 million of accelerated amortization expense related to the termination of a hospital contract associated with a prior acquisition.

Income from operations increased $36.9 million, or 16.2%, to $263.9 million for the nine months ended September 30, 2011, as compared to $227.0 million for the same period in 2010. Our operating margin increased 32 basis points, to 22.3% for the nine months ended September 30, 2011, as compared to 22.0% for the same period in 2010. This increase of 32 basis points was primarily due to the favorable impact of recent acquisitions, offset by net increases in operating expenses.

We recorded net interest expense of $2.0 million for the nine months ended September 30, 2011, as compared to $1.2 million for the same period in 2010. The increase in net interest expense was primarily due to higher average borrowings under our Line of Credit, a lower rate of return on our investments and an increase in accretion expense related to our contingent consideration liabilities, partially offset by a lower effective interest rate on our Line of Credit. Interest expense for the nine months ended September 30, 2011 and 2010 consisted primarily of interest charges, commitment fees and amortized debt costs associated with our Line of Credit and accretion expense related to our contingent consideration liabilities.

Our effective income tax rate was 39.0% for the nine months ended September 30, 2011, as compared to 34.1% for the nine months ended September 30, 2010. The income tax rate for the nine months ended September 30, 2010 reflects a $10.9 million reduction in our income tax provision resulting from the resolution of certain matters that were under review with taxing authorities. Excluding the favorable impact of the tax matters resolution, our effective income tax rate was 38.9% for the nine months ended September 30, 2010. We believe that excluding the favorable impact from the tax matters resolution provides a more meaningful comparison of the effective income tax rate.

Net income increased by 7.2% to $159.6 million for the nine months ended September 30, 2011, as compared to $148.9 million for the same period in 2010. Net income for the nine months ended September 30, 2010 includes a $10.9 million increase related to a reduction in our income tax provision resulting from the resolution of certain matters that were under review with taxing authorities. Excluding the favorable impact of the tax matters resolution, our net income increased by 15.7% to $159.6 million for the nine months ended September 30, 2011, as compared to $138.0 million for the same period in 2010. We believe that excluding the favorable impact from the tax matters resolution provides more meaningful comparison of net income.

Diluted net income per common and common equivalent share was $3.28 on weighted average shares outstanding of 48.7 million for the nine months ended September 30, 2011, as compared to $3.14 on weighted average shares outstanding of 47.4 million for the same period in 2010. Diluted net income per common and common equivalent share for the nine months ended September 30, 2010 reflects a $10.9 million reduction in our income tax provision, or an increase of $0.23 per common and common equivalent share, resulting from the resolution of certain matters that were under review with taxing authorities. Excluding the favorable impact of the tax matters resolution, our diluted net income per common and common equivalent share was $2.91 for the nine months ended September 30, 2010. We believe that excluding the favorable impact from the tax matters resolution provides a more meaningful comparison of diluted net income per common and common equivalent share.

Liquidity and Capital Resources

As of September 30, 2011, we had $35.7 million of cash and cash equivalents on hand as compared to $26.3 million at December 31, 2010. In addition, we had working capital of $118.9 million at September 30, 2011, an increase of $44.0 million from working capital of $74.9 million at December 31, 2010. This net increase in working capital is primarily due to year-to-date earnings and proceeds from the issuance of common stock under our stock incentive and stock purchase plans, partially offset by the use of funds for payments on our Line of Credit, physician practice acquisition payments and capital expenditures.

Our net cash provided from operating activities was $180.9 million for the nine months ended September 30, 2011, as compared to net cash provided from operating activities of $155.5 million for the same period in 2010. This net improvement of $25.4 million for the nine months ended September 30, 2011 is primarily due to: (i) a net increase in cash flow from operations related to changes in the components of our accounts payable and accrued expenses, consisting primarily of changes in our accrued incentive compensation liability and (ii) improved operating results; partially offset by (iii) a net decrease in cash flow related to changes in our income tax liabilities, resulting primarily from higher estimated tax payments and (iv) a reduction in cash flow related to higher accounts receivable balances from higher net patient service revenue recorded during the nine months ended September 30, 2011.

During the nine months ended September 30, 2011, accounts receivable increased by $25.7 million, as compared to an increase of $10.3 million for the same period in 2010. The net increase in accounts receivable for the nine months ended September 30, 2011, as compared to the same period in 2010, is primarily due to higher same-unit revenue growth during the period, as well as an increase in accounts receivable related to recent acquisitions.

Our accounts receivable are principally due from managed care payors, government payors, and other third-party insurance payors. We track our collections from these sources, monitor the age of our accounts receivable, and make all reasonable efforts to collect outstanding accounts receivable through our systems, processes and personnel at our corporate and regional billing and collection offices. We use customary collection practices, including the use of outside collection agencies, for accounts receivable due from private pay patients when appropriate. Almost all of our accounts receivable adjustments consist of contractual adjustments due to the difference between gross amounts billed and the amounts allowed by our payors. Any amounts written off related to private pay patients are based on the specific facts and circumstances related to each individual patient account.

Days sales outstanding (“DSO”) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO was 46.7 days at September 30, 2011 as compared to 45.3 days at December 31, 2010. The increase in DSO was primarily due to the increase in accounts receivable related to recent acquisitions.

During the nine months ended September 30, 2011, cash used in operating activities related to accounts payable and accrued expenses was $13.2 million, compared to $51.8 million for the same period in 2010. The net decrease in cash used of $38.6 million related to accounts payable and accrued expenses activities is primarily due to (i) a decrease in our annual payments due under our performance-based incentive compensation program of which a majority is paid in the first quarter of each year, (ii) an increase in our accruals for performance-based incentive compensation during the nine months ended September 30, 2011 and (iii) a change in reserves for uncertain tax positions, on a comparative basis, due to a decrease that was recorded during the nine months ended September 30, 2010 resulting from the resolution of certain tax matters that were under review with taxing authorities.

During the nine months ended September 30, 2011, our net cash used in investing activities of $106.0 million included physician practice acquisition payments and contingent purchase price payments of $79.9 million, capital expenditures of $28.6 million, and net proceeds of $2.5 million related to the purchase and maturity of investments. Our capital expenditures were $18.5 million for an office building and $10.1 million for medical equipment, computer and office equipment, software, furniture and fixtures, and leasehold and other improvements at our office-based practices and our corporate and regional offices. Our acquisition payments were primarily related to the purchase of seven physician practices, including three maternal-fetal medicine practices, one neonatology practice, one pediatric cardiology practice, one other pediatric subspecialty practice and one anesthesiology practice.

During the nine months ended September 30, 2011, our net cash used in financing activities of $65.4 million consisted primarily of net payments on our Line of Credit of $96.5 million and payments of $3.7 million for contingent consideration liabilities, partially offset by proceeds from the exercise of employee stock options and the issuance of common stock under our stock purchase plans of $28.3 million and excess tax benefits related to the vesting of restricted stock and the exercise of employee stock options of $6.9 million. Under the current accounting guidance for business combinations, payments of contingent consideration liabilities related to acquisitions completed after January 1, 2009 are presented as cash flows from financing activities. Payments of contingent consideration liabilities related to acquisitions completed prior to January 1, 2009 are presented as cash flows from investing activities.

At September 30, 2011, we had an outstanding principal balance of $50.0 million on our Line of Credit. We also had outstanding letters of credit associated with our professional liability insurance program of $5.3 million which reduced the amount available on our Line of Credit to $294.7 million at September 30, 2011.

On October 21, 2011, we entered into an amended and restated credit agreement (“Amended and Restated Line of Credit”) which increased the borrowing capacity thereunder to $500 million from $350 million. The Amended and Restated Line of Credit matures on October 21, 2016.

The Amended and Restated Line of Credit, which is guaranteed by substantially all of our subsidiaries and affiliated professional associations and corporations, includes (1) a $50 million sub-facility for the issuance of letters of credit and (2) a $25 million sub-facility for swingline loans. The Amended and Restated Line of Credit may be increased up to $570 million, subject to the satisfaction of specified conditions. At our option, borrowings under the Amended and Restated Line of Credit (other than swingline loans) bear interest at (1) the alternate base rate (defined as the highest of (i) the Wells Fargo Bank, National Association prime rate, (ii) the Federal Funds Rate plus 1/2 of 1% and (iii) one month LIBOR plus 1%) or (2) the LIBOR rate, as defined in the Amended and Restated Line of Credit, plus an applicable margin rate ranging from 0.125% to 0.5% for alternate base rate borrowings and 1.125% to 1.5% for LIBOR rate borrowings, in each case based on our consolidated leverage ratio. Swingline loans bear interest at the alternate base rate plus the applicable margin rate. We are subject to certain covenants and restrictions specified in the Amended and Restated Line of Credit, including covenants that require us to maintain a minimum fixed charge coverage ratio and not to exceed a specified consolidated leverage ratio, to comply with laws, and restrict us from paying dividends and making certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended and Restated Line of Credit, notwithstanding our ability to meet our debt service obligations. The Amended and Restated Line of Credit includes various customary remedies for the lenders following an event of default.

At September 30, 2011, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us. The evaluation of our compliance with the financial covenants and other restrictions as of September 30, 2011 was performed in accordance with the Amended and Restated Line of Credit. Based on our current expectations, we believe we will be in compliance with these covenants and other restrictions throughout 2011.

We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at September 30, 2011 was $123.4 million, of which $11.7 million is classified as a current liability within accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets.

We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Amended and Restated Line of Credit, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, and meet our contractual obligations for at least the next 12 months.

Caution Concerning Forward-Looking Statements

Certain information included or incorporated by reference in this Quarterly Report may be deemed to be forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K, including the section entitled “Risk Factors.”

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our Line of Credit is subject to market risk and interest rate changes. The outstanding principal balance on our Line of Credit was $50.0 million at September 30, 2011. Considering the total outstanding balance of $50.0 million, a 1% change in interest rates would result in an impact to income before income taxes of approximately $0.5 million per year. See Note 12 to our Condensed Consolidated Financial Statements in this Form 10-Q for more information regarding our Line of Credit which was amended and restated on October 21, 2011.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this report.

Changes in Internal Controls Over Financial Reporting

No changes in our internal control over financial reporting occurred during the quarter ended September 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

In September 2006, we entered into a settlement agreement with the Department of Justice and a relator who initiated a “qui tam” complaint against us relating to our billing practices for services provided from January 1996 through December 1999 that were reimbursed by Medicaid, the Federal Employees Health Benefit program, and the United States Department of Defense’s TRICARE program for military dependents and retirees (the “Settlement Agreement”). As part of the Settlement Agreement, we were under a five-year Corporate Integrity Agreement (“CIA”) with the OIG which expired on September 20, 2011. A final report regarding our compliance with the CIA will be filed with the OIG. Although the term of the CIA has expired, we intend to continue the existence of our comprehensive Compliance Plan which provides for policies and procedures aimed at promoting compliance with healthcare laws and regulations.

In July 2007, the Audit Committee of our Board of Directors concluded a comprehensive review of our historical practices related to the granting of stock options. In connection with the review, we had discussions with the U.S. Attorney’s office for the Southern District of Florida concerning the matters covered by the review and, in response to a subpoena received in December 2007, provided the office with various documents and information related to our stock option granting practices. We intend to fully cooperate with the U.S. Attorney’s office if there is any additional activity with respect to this matter. In March 2009, we settled an investigation by the Securities and Exchange Commission relating to this matter by entering into a consent decree.

We expect that additional audits, inquiries and investigations from government authorities and agencies will continue to occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows, or the trading price of our common stock.

In the ordinary course of business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians. We may also become subject to other lawsuits which could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition or results of operations. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations and the trading price of our common stock.

Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, we generally self-insure a portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition and results of operations.

Item 1A.

Risk Factors

There have been no material changes to the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Item 6.

Exhibits

See Exhibit Index.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	MEDNAX, INC.

Date: November 1, 2011	By:	/s/ Roger J. Medel, M.D.
		Roger J. Medel, M.D.
		Chief Executive Officer
		(Principal Executive Officer)

Date: November 1, 2011	By:	/s/ Vivian Lopez-Blanco
		Vivian Lopez-Blanco
		Chief Financial Officer and Treasurer
		(Principal Financial Officer and
		Principal Accounting Officer)

EXHIBIT INDEX


Exhibit No.		Description

10.1		Employment Agreement, dated August 7, 2011, by and between Mednax Services, Inc. and Roger J. Medel, M.D. (incorporated by reference to Exhibit 10.1 to MEDNAX’s Current Report on Form 8-K dated August 10, 2011).

10.2		Restricted Shares Units Agreement for Roger J. Medel, M.D., dated August 7, 2011 (incorporated by reference to Exhibit 10.2 to MEDNAX’s Current Report on Form 8-K dated August 10, 2011).

31.1+		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32+		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS++		XBRL Instance Document.

101.SCH++		XBRL Taxonomy Extension Schema Document.

101.CAL++		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF++		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB++		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE++		XBRL Taxonomy Extension Presentation Linkbase Document.

+	Filed herewith.

++	Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration

statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability

under those sections.

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Roger J. Medel, M.D., certify that:

I have reviewed this quarterly report on Form 10-Q of MEDNAX, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2011


By:		/s/ Roger J. Medel, M.D.
		Roger J. Medel, M.D.
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Vivian Lopez-Blanco, certify that:

I have reviewed this quarterly report on Form 10-Q of MEDNAX, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2011


By:		/s/ Vivian Lopez-Blanco
		Vivian Lopez-Blanco
		Chief Financial Officer and Treasurer
		(Principal Financial Officer and
		Principal Accounting Officer)

EX-32

Exhibit 32

Certification Pursuant to 18 U.S.C Section 1350

(Adopted by Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with the Quarterly Report of MEDNAX, Inc. on Form 10-Q for the quarter ended September 30, 2011 (the “Report”), each of the undersigned hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of MEDNAX, Inc.

A signed original of this written statement required by Section 906 has been provided to MEDNAX, Inc. and will be retained by MEDNAX, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

November 1, 2011


By:		/s/ Roger J. Medel, M.D.
		Roger J. Medel, M.D.
		Chief Executive Officer
		(Principal Executive Officer)

By:		/s/ Vivian Lopez-Blanco
		Vivian Lopez-Blanco
		Chief Financial Officer and Treasurer
		(Principal Financial Officer and
		Principal Accounting Officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company